Konference: 2008 33st Congress ESMO - účast ČR
Kategorie: Kolorektální karcinom
Téma: Colorectal cancer
Číslo abstraktu: 447
Autoři: MUDr. Jana Halámková, Ph.D.; doc. MUDr. Igor Kiss, Ph.D., MBA; MUDr. Zdeněk Pavlovský; Z. Čech; MUDr. Jiří Tomášek, Ph.D.; MUDr. Štěpán Tuček, PhD.; Mgr. Adam Svobodník, Ph.D.; Lada Hanákova, staniční sestra; MUDr. Mojmír Moulis; prof. MUDr. Miroslav Penka, CSc.
Methods: Peripheral blood samples for analysis PAI 1 and the tumour tissue were obtained from 31 patients preoperatively, or before the start of chemotherapy. Another sample was taken subsequently 4-6 weeks after from 28 patients. Analysis of gene polymorphism PAI 1 was obtained from 30 patients. The proof of uPA, uPAR, PAI 1 and PAI 2 in the tumour tissue was based on imunohistochemical reaction with polyclonal antibodies. For analysis of PAI 1 in the peripheral blood was used reaction set Spectrolyse®/pL PAI. For the need of genetic polymorphisms PAI 1 was using a standard method of ‘‘QIA Blood Mini Kit’’.
Results and conclusion: There was significant correlation between PAI 1 (p=0.011)and PAI 2 (p=0.007) in the tumour tissue and stage. In advanced cancer higher expression of uPAR in the tumour tissue was proven (p=0.005). PAI 1 plasmatic level was higher in the advanced stages before and after surgery but this increase was not statistically significant. There was significant correlation between levels of PAI 1 before and after treatment (r=0.817; p<0.001). Antigen levels of uPA, uPAR, PAI 1 and 2 were higher in advanced tumours. There was no statistical correlation between the stage of the disease and genetic polymorphisms PAI 1. For evaluation of role of PAS in colorectal carcinoma a longer follow up will be needed as well as more heterogenous group of patients.
Datum přednesení příspěvku: 12. 9. 2008